| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing precisely teicoplanin 400 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epoprostenol (as epoprostenol sodium) 500 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely epoprostenol (as epoprostenol sodium) 500 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Interferon alfa-2b 1 million unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Interferon alfa-2b 1 million unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely sargramostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely sargramostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely tenoxicam 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely tenoxicam 20 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely etanercept 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely etanercept 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely indometacin (as indometacin sodium trihydrate) 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely indometacin (as indometacin sodium trihydrate) 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ticarcilline 3 g/acide clavulanique 200 mg, fiole de poudre pour perfusion (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| ticarcilline 3 g/acide clavulanique 200 mg, fiole de poudre pour perfusion (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| ticarcilline 3 g/acide clavulanique 200 mg, fiole de poudre pour perfusion (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Peginterferon alfa-2b 50 microgram powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Peginterferon alfa-2b 50 microgram powder for solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epirubicin hydrochloride 20 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epirubicin hydrochloride 20 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Coagulation factor XIII 1250 unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Coagulation factor XIII 1250 unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epirubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epirubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely coagulation factor XIII 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely coagulation factor XIII 250 unit/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Topotecan (as topotecan hydrochloride) 1 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Peginterferon alfa-2b 120 microgram powder for solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Peginterferon alfa-2b 120 microgram powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 2.49 g and palmitic acid 2.5 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Trastuzumab 150 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Trastuzumab 150 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| Galactose 3.99 g and palmitic acid 4 mg powder for suspension for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Pentostatin 10 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Pentostatin 10 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely glucagon hydrochloride 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely glucagon hydrochloride 1 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely etanercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely etanercept 25 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ganciclovir 500 mg, fiole de poudre pour perfusion (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| ganciclovir 500 mg, fiole de poudre pour perfusion (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely gonadorelin (as gonadorelin hydrochloride) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely gonadorelin (as gonadorelin hydrochloride) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 40 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely molgramostim 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely molgramostim 150 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely romiplostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely romiplostim 250 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| floxacilline 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| floxacilline 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Product containing precisely mitomycin 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely mitomycin 10 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| méropenem 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| méropenem 500 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Mitomycin 2 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Mitomycin 2 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Infliximab 100 mg powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Infliximab 100 mg powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Imiglucerase 200 unit powder for solution for injection vial |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| Imiglucerase 200 unit powder for solution for injection vial |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| pipéracilline 2 g/tazobactam 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
1 |
| pipéracilline 2 g/tazobactam 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has presentation strength denominator unit (attribute) |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
2 |
| pipéracilline 2 g/tazobactam 250 mg, fiole de poudre pour solution injectable (médicament clinique) |
Has unit of presentation |
True |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Fluconazole 50 mg/25 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Atracurium besylate 250 mg/25 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely fluorouracil (as fluorouracil sodium) 2.5 gram/100 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely disodium pamidronate 60 milligram/20 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely fluorouracil (as fluorouracil sodium) 250 milligram/10 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely disodium pamidronate 90 milligram/30 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely dobutamine (as dobutamine hydrochloride) 250 milligram/20 milliliter conventional release solution for infusion vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Fluphenazine decanoate 250 mg/10 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely doxorubicin hydrochloride 200 milligram/100 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Eculizumab 300 mg/30 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely buserelin (as buserelin acetate) 5.5 milligram/5.5 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Edrophonium chloride 150 mg/15 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely epirubicin hydrochloride 200 milligram/100 milliliter conventional release solution for infusion vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cidofovir 375 mg/5 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epirubicin hydrochloride 10 mg/5 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cladribine 10 mg/10 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely abciximab 10 milligram/5 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely fluorouracil (as fluorouracil sodium) 500 milligram/20 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Acetaminophen 500 mg/50 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely aciclovir (as aciclovir sodium) 500 milligram/20 milliliter conventional release solution for infusion vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Acyclovir (as acyclovir sodium) 1 g/40 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Acyclovir (as acyclovir sodium) 250 mg/10 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely cytarabine 1 gram/10 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Adenosine 30 mg/10 mL solution for infusion vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cytarabine 100 mg/mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely adenosine 6 milligram/2 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cytarabine 2 g/20 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cytarabine 500 mg/5 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Epoetin alfa 40000 unit/mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Product containing precisely bevacizumab 400 milligram/16 milliliter conventional release solution for injection vial (clinical drug) |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Cytarabine 500 mg/25 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
| Bevacizumab 100 mg/4 mL solution for injection vial |
Has unit of presentation |
False |
Vial (unit of presentation) |
Inferred relationship |
Some |
|
FHIR